Williams, Henry Schein, and 3 Other Bargain Stocks From a Veteran Value Fund Manager
A veteran value fund manager has identified several bargain stocks, including Williams and Henry Schein, amidst a volatile market. Value stocks have outperformed growth stocks this year, with the Vanguard Value ETF up 3.3% while the Vanguard Growth ETF has fallen 9.5%. This article highlights opportunities for investors seeking reasonably priced growth stocks.
Henry Schein Inc. stock outperforms competitors on strong trading day
Henry Schein Inc. (HSIC) shares advanced 1.24% to $74.86 on Monday, performing strongly in a generally positive trading session for the stock market. This marks the second consecutive day of gains for the company's stock. The S&P 500 Index and Dow Jones Industrial Average also saw increases.
Assessing McKesson (MCK) Valuation After Upward Earnings Revisions And Strength In Pharmaceutical Distribution
McKesson (MCK) is currently valued at US$884.28 and appears undervalued with a narrative fair value of approximately US$997.67, according to Simply Wall St. Recent upward earnings revisions and its strong performance in exceeding EPS estimates, coupled with benefits from a complex pharmaceutical supply chain, contribute to its positive outlook. Investors are advised to consider both the rewards and risks, such as potential tighter drug pricing regulations, before making investment decisions.
Henry Schein, Inc. (NASDAQ:HSIC) Receives Average Recommendation of "Hold" from Brokerages
Henry Schein, Inc. (NASDAQ:HSIC) has received a consensus "Hold" rating from thirteen brokerages, with an average one-year price target of $85.58. The company recently surpassed quarterly earnings and revenue expectations and issued an FY2026 EPS guidance above analyst consensus. Despite insider sales totaling approximately $8.57 million over the last three months, institutional investors maintain a significant 96.62% stake in the company.
HSIC.O PE Ratio & Valuation, Is HSIC.O Overvalued
Henry Schein Inc (HSIC.O) is currently considered undervalued, with a forward P/E ratio of 13.77 compared to its five-year average of 15.50. Its fair price is estimated to be between $83.03 and $98.49, indicating it is undervalued by 10.95% relative to its current price of $73.94. The article also details other valuation metrics like P/B ratio, FCF yield, and P/S ratio, contrasting them with historical averages and competitor benchmarks.
HSIC Should I Buy
This article provides an analysis of Henry Schein Inc. (HSIC) stock, including analyst ratings and price targets. Wall Street analysts forecast a 10% rise in HSIC.O stock price, with a "Moderate Buy" consensus based on 5 buy, 3 hold, and 2 sell ratings. Recent updates from Mizuho and JPMorgan reflect increased price targets and positive outlooks following the company's Q4 report.
DaVita's "Move It With Purpose" Sets Record Participation in Support of Global Health
DaVita's third annual "Move It With Purpose" (MIWP) event achieved record participation, with over 8,300 individuals logging 550,000 miles of activity across nearly 150 events. This initiative raised more than $750,000 for Bridge of Life, a nonprofit founded by DaVita, to support chronic disease prevention and treatment globally. Since 2007, DaVita has raised over $15 million for Bridge of Life, helping nearly 150,000 individuals in 34 countries.
231,651 Shares in Henry Schein, Inc. $HSIC Acquired by Tudor Investment Corp ET AL
Tudor Investment Corp ET AL acquired a new stake of 231,651 shares in Henry Schein, valued at approximately $15.38 million, representing about 0.20% of the company. Henry Schein surpassed quarterly earnings expectations, reporting $1.34 EPS against an estimated $1.30, and revenue of $3.44 billion, exceeding the $3.34 billion forecast, while institutional investors now own 96.62% of the stock. Despite this, there has been notable insider selling, with CEO Stanley M. Bergman selling 43,812 shares, and other insiders collectively selling over 105,911 shares in the past 90 days.
HSIC Technical Analysis & Stock Price Forecast
This article provides a technical analysis of Henry Schein Inc. (HSIC), indicating a current "Buy" consensus based on various technical signals. It details key indicators such as RSI, MACD, support/resistance levels, and moving averages, offering insights into the stock's current momentum and potential price movements. The analysis concludes that while some indicators suggest a sell, a majority point towards a buy for HSIC.
Assessing Henry Schein (HSIC) Valuation As Recent Share Price Moves Draw Fresh Attention
The article evaluates Henry Schein (HSIC) stock after recent price movements, noting it trades at a significant discount to its estimated intrinsic value and analyst targets. It highlights the company's growth in high-margin sectors and investments in digital healthcare, contributing to a "narrative fair value" of $90, suggesting it is undervalued. However, it also cautions that competitive pressures and staffing issues could impact future performance.
Do Earnings Revisions And Value-Based Care Momentum Change The Bull Case For McKesson (MCK)?
McKesson (MCK) has seen positive earnings estimate revisions and consistent EPS beats, driven by its pharmaceutical distribution and growing role in value-based care. While these factors support a strong near-term outlook, potential risks related to drug pricing policy remain significant. The company's future performance will depend on its ability to leverage its scale and services amidst regulatory pressures, with current forecasts projecting a substantial increase in revenue and earnings by 2029.
Dental Equipment & Technology Stocks Q4 Recap: Benchmarking Align Technology (NASDAQ:ALGN)
This article reviews the Q4 performance of several dental equipment and technology stocks, highlighting Align Technology (NASDAQ:ALGN), Envista (NYSE:NVST), Dentsply Sirona (NASDAQ:XRAY), and Henry Schein (NASDAQ:HSIC). While the sector collectively saw a strong Q4 with revenues beating estimates, share prices have averaged a slight decline. The piece also briefly touches on broader market concerns shifting from AI disruption to geopolitical risks in early 2026.
Henry Schein Inc. stock outperforms competitors on strong trading day
Shares of Henry Schein Inc. (HSIC) rallied 1.23% to $73.94, outperforming the mixed stock market Thursday as the S&P 500 Index rose and the Dow Jones Industrial Average fell. The company's stock closed 17.19% below its 52-week high.
Dental Equipment & Technology Stocks Q4 Recap: Benchmarking Align Technology (NASDAQ:ALGN)
This article provides a Q4 recap of dental equipment and technology stocks, focusing on companies like Align Technology (ALGN), Envista Holdings (NVST), Dentsply Sirona (XRAY), and Henry Schein (HSIC). It details their revenue performance against analyst expectations, highlighting Envista as the strongest performer and Align Technology showing the weakest performance against estimates, despite a stock price increase. The piece also touches on industry trends, including innovation and challenges like economic uncertainty and regulatory pressures.
Align Technology Inc Stock: Invisalign Leader Faces Evolving Orthodontics Market in 2026
Align Technology Inc., known for its Invisalign clear aligners, holds a dominant position in the digital orthodontics market. The company's success is driven by its direct-to-consumer model, proprietary software, and global expansion, particularly in North America. While facing competition and macroeconomic headwinds, Align continues to innovate with AI-enhanced simulations and international growth strategies.
Align Technology Inc Stock: Invisalign Leader Faces Evolving Orthodontics Market in 2026
Align Technology Inc, known for its Invisalign clear aligners, holds a strong position in the digital orthodontics market. The company's business model leverages precision manufacturing and digital services, primarily through Invisalign sales and the iTero scanner ecosystem. While facing competition from 3D printing startups and traditional braces, Align sustains its market lead through intellectual property, partnerships, and an innovation pipeline, with analysts holding a consensus "hold" rating due to balanced growth prospects and valuation concerns.
Growth Patterns, Segment Analysis, and Competitive Approaches Influencing the Dental Preventive Supplies Market
The global dental preventive supplies market is projected to reach $6.57 billion by 2030, growing at a CAGR of 5.6% due to increased oral health awareness, product innovations, and expanding dental services. Key players like Procter & Gamble and Colgate-Palmolive are driving growth with new products, such as antibacterial oral care regimens. The market is segmented by product type, material, distribution channel, application, and end-user, reflecting diverse consumer needs.
Brookstone Capital Management Increases Stake in McKesson Corporation $MCK
Brookstone Capital Management raised its stake in McKesson Corporation by 18.8% in Q4, now owning 13,821 shares valued at $11.34 million. McKesson exceeded Q4 earnings expectations with an EPS of $9.34 and revenues of $106.16 billion, also providing strong FY2026 EPS guidance. Despite some insider selling, institutional investors own 85.07% of the stock, and analysts maintain a "Moderate Buy" rating for the company.
North America Clear Aligners and Retainers Market Is Going
This report provides a comprehensive analysis of the North America Clear Aligners and Retainers Market, covering trends, growth drivers, challenges, and opportunities from 2026-2033. It includes competitor analysis featuring companies like Align Technology Inc. and 3M Company, market segmentation, and details on research methodologies. The report aims to help market participants make informed strategic decisions and forecast future profitability.
William Blair Maintains Henry Schein(HSIC.US) With Hold Rating
William Blair has reiterated its Hold rating on Henry Schein (HSIC.US). This indicates that the firm advises investors to maintain their current positions in the stock without recommending buying or selling. The company's stock symbol is HSIC.US.
Henry Schein Inc. stock rises Tuesday, still underperforms market
Shares of Henry Schein Inc. (HSIC) increased by 1.38% to $73.70 on Tuesday, despite the stock still underperforming the broader market. This rise occurred during an overall positive trading session, with the S&P 500 Index and Dow Jones Industrial Average also seeing significant gains. This marks the second consecutive day of gains for Henry Schein Inc. stock.
Henry Schein Inc Stock: A Steady Force in Dental and Medical Distribution for North American Investo
Henry Schein Inc is a leading distributor of dental, medical, and veterinary products, holding a robust position in North American healthcare supply chains. The company's diversified operations, strong distribution network, and strategic investments in digital dentistry and technology-enabled services contribute to its resilience. For investors, Henry Schein offers exposure to steady demand in healthcare essentials, supported by a dividend policy and lower volatility compared to pure tech or pharma peers.
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Encompass Health (EHC) and Merck & Company (MRK)
This article highlights positive analyst insights for three healthcare companies: Henry Schein (HSIC), Encompass Health (EHC), and Merck & Company (MRK). Analysts from Barclays and KeyBanc maintained "Buy" ratings and provided price targets, reflecting bullish sentiments within the Healthcare sector. The report also notes consensus ratings and potential upsides for each stock based on analyst projections.
Dental Floss Market Is Going to Boom | 3M, Dr Wild & Co. AG, Sunstar Suisse SA, The humble Co.
The dental floss market is projected to grow from USD 727.6 million in 2026 to USD 978.9 million by 2033, exhibiting a CAGR of 6%. This growth is driven by innovation, increased investment, and changing regional dynamics, requiring strategic insights for decision-makers. The report offers detailed analysis including market segmentation, financial breakdowns of major players, and regional coverage to help stakeholders capitalize on market opportunities.
Dental Sealant Market Is Going to Boom | 3M • Kerr Corporation • Dentsply Sirona • Henry Schein
Coherent Market Insights has published a comprehensive report titled "Dental Sealant Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033." This report offers an in-depth analysis of market competition, geographic distribution, and growth potential, along with critical success factors, risk assessment, and economic analysis. It identifies major market players as 3M, Kerr Corporation, Dentsply Sirona, and Henry Schein, and details market segmentation across pediatric dentistry, general dentistry, orthodontics, preventive care, dental clinics, hospitals, dental laboratories, and home care products.
Henry Schein: A Cash-Generating Healthcare Distributor Priced for Mediocrity
Henry Schein is a major global distributor of healthcare products, particularly in dental and medical markets, generating around $12.7 billion in revenue in 2024. While the company demonstrates consistent cash generation and strategic capital allocation, its operating and net margins have declined significantly over the past decade. The investment case hinges on the stability of its current, lower margin profile, rather than a return to past profitability, suggesting that the stock is priced for durability and incremental per-share growth through buybacks, amidst evolving governance and operational risks.
Assenagon Asset Management S.A. Buys 45,701 Shares of Henry Schein, Inc. $HSIC
Assenagon Asset Management S.A. significantly increased its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 212.8% in the fourth quarter, purchasing an additional 45,701 shares to hold a total of 67,181 shares valued at approximately $5.08 million. This comes as company insiders have sold over 105,911 shares worth $8.57 million in the last quarter, yet institutional investors now own 96.62% of the stock. Henry Schein also reported beating Q4 earnings estimates, with EPS of $1.34 against an anticipated $1.30, and provided FY2026 guidance, maintaining a consensus "Hold" rating from analysts with an average price target of $85.58.
Henry Schein stock drops 2.18% as company recognized among World’s Most Ethical Companies
Henry Schein's stock (HSIC) dropped 2.18% despite the company being recognized for the 15th consecutive year as one of Ethisphere's World’s Most Ethical Companies. The stock is currently trading below all major daily moving averages, indicating a sustained bearish momentum. Technical analysis suggests HSIC is likely to move sideways in the coming week with a risk of further downside if key support levels are breached.
Henry Schein Inc Stock: A Steady Force in Dental and Medical Distribution for Long-Term Investors
Henry Schein Inc is presented as a stable investment in the dental, medical, and veterinary supplies distribution sectors. The company's diversified business model across these healthcare segments, its global reach, and integrated service offerings contribute to its strong market position and appeal to long-term investors. Despite potential macroeconomic pressures and competition, its essential role in healthcare delivery and focus on recurring revenue streams position it for predictable growth paths.
Henry Schein Inc Stock: A Steady Force in Dental and Medical Distribution for Long-Term Investors
Henry Schein Inc is presented as a stable investment in healthcare distribution, focusing on dental, medical, and animal health supplies. The company's diversified business model, global reach, and recurring revenue from consumables contribute to its resilience. It is seen as a suitable core holding for North American investors seeking defensive healthcare exposure with steady demand and growth potential.
Henry Schein (HSIC) price target increased by 12.37% to 90.80
This article announces that the price target for Henry Schein (HSIC) has been increased by 12.37%, bringing it to $90.80. The content provided is minimal, only stating the price target adjustment.
MCK (McKesson) Enterprise Value : $112,223 Mil (As of Mar. 28, 2026) ***
This article provides a detailed analysis of McKesson Corp's (NYSE:MCK) Enterprise Value as of March 28, 2026, which stands at $112,223 Million. It breaks down various valuation ratios such as EV-to-EBIT, EV-to-EBITDA, EV-to-Revenue, EV-to-OCF, and EV-to-FCF, explaining their calculations based on the company's financial data up to December 2025. The article also notes that McKesson is considered "Modestly Overvalued" by GuruFocus, with a GF Score of 82/100 and two warning signs for investors.
Henry Schein (HSIC) down 9.4% since last earnings report: Can it rebound?
This article discusses Henry Schein's (HSIC) stock performance, noting a 9.4% decline since its last earnings report. It implies the article will analyze reasons for the dip and assess the potential for a rebound.
Henry Schein Inc. stock underperforms Friday when compared to competitors
Henry Schein Inc. (HSIC) stock fell 2.18% to $72.10 on Friday, underperforming major indexes like the S&P 500 Index and Dow Jones Industrial Average, which also experienced declines. This marks the second consecutive day of losses for the company's stock.
Vanguard Reports 0 Shares in Henry Schein After Realignment (NASDAQ: HSIC)
Vanguard has reported holding 0 shares of Henry Schein (NASDAQ: HSIC) common stock, representing 0% beneficial ownership, following an internal realignment on January 12, 2026. This change is documented in an amended Schedule 13G/A filing, indicating that certain Vanguard subsidiaries will now report their ownership separately in accordance with SEC Release No. 34-39538. Despite the adjustment in reporting, the filing notes no positive or negative impact on the company.
Henry Schein One Drives Growth with Cloud-Based Dental Solutions and AI Integration
Henry Schein One, a joint venture of Henry Schein Inc., is leading the dental technology sector by focusing on cloud-based practice management tools and integrating generative AI from Amazon Web Services. This strategy aims to enhance efficiency, streamline operations, and improve customer satisfaction for dental practices. The company also employs strategic acquisitions and partnerships to expand its offerings, customer base, and market reach, despite challenges like macroeconomic factors and market competition.
Henry Schein One Drives Growth with Cloud-Based Dental Solutions and AI Integration
Henry Schein One, a joint venture of Henry Schein Inc., is leading the dental technology sector by focusing on cloud-based practice management tools and integrating Amazon Web Services' generative AI. This strategic approach, combined with acquisitions and partnerships, aims to enhance efficiency, attract clients, and strengthen its market presence despite macroeconomic factors and increasing competition. The company is actively expanding its offerings through collaborations, such as with Oral Genome, to provide advanced and personalized dental solutions.
Henry Schein One Drives Growth with Cloud-Based Dental Solutions and AI Integration
Henry Schein One, a joint venture of Henry Schein Inc., is driving growth in the dental technology sector by focusing on cloud-based practice management tools and integrating Amazon Web Services' generative AI technologies. This strategy aims to enhance efficiency, customer satisfaction, and market presence through digital workflows, strategic acquisitions, and partnerships. Despite facing macroeconomic challenges and fierce competition, the company continues to expand its offerings and market reach.
How Investors May Respond To Henry Schein (HSIC) Strong Q4 Specialty Products-Driven Margin Expansion
Henry Schein reported strong Q4 2025 results, driven by a 14.6% increase in Global Specialty Products sales, which boosted margins. This performance aligns with the company's strategy to shift towards higher-margin specialty and software offerings. The article suggests this strengthens the investment narrative, supported by share repurchases, but also cautions investors about ongoing competitive pricing pressures and the impact of value implants on future margin gains.
Henry Schein (HSIC) Goldman Sachs 45th Annual Global Healthcare Conference Summary
This article summarizes Henry Schein's (HSIC) presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. Key takeaways include trends in the dental market, specifically a slow start to 2024 due to external factors but subsequent recovery, stable patient traffic, and expected market expansion from new dentists. The summary also touches upon international market dynamics, equipment and service trends, and lists other recent investor events for Henry Schein.
Should You Keep Henry Schein Shares in Your Investment Portfolio at This Time?
Henry Schein, Inc. (HSIC) is experiencing growth fueled by its Henry Schein One joint venture's expansion into cloud-based software and strategic acquisitions and partnerships. Despite these positive drivers, the company faces challenges from global economic pressures, including currency volatility and inflation, along with intense competition in the healthcare distribution sector. Investors are advised to consider these factors when evaluating HSIC, which holds a Zacks Rank #3 (Hold), especially given its recent earnings performance and future forecasts.
Should You Retain Henry Schein Stock in Your Portfolio for Now?
Henry Schein is experiencing strong growth through its Henry Schein One joint venture, which is expanding its cloud-based practice management software and integrating AI technologies via a new partnership with Amazon Web Services. The company also drives revenue growth through strategic acquisitions and partnerships, enhancing its product lines and distribution channels. However, macroeconomic challenges like inflation and fierce competition in the healthcare products and services industry pose significant headwinds, impacting its financial operations and margins.
Henry Schein stock faces uncertain trading amid lack of fresh catalysts in dental distribution secto
Henry Schein stock (HSIC) is trading stably in a mature market but lacks immediate catalysts, according to an analysis from March 24, 2026. Despite its strong position in dental, medical, and veterinary supplies, the company's immediate growth prospects are tempered by slow sector-wide developments. US investors are advised to consider its defensive qualities and steady demand for essential supplies rather than expecting rapid growth.
Cardinal Health sets April 30 webcast for fiscal Q3 results
Cardinal Health (NYSE: CAH) announced it will release its third-quarter fiscal year 2026 results on April 30, 2026, before the New York Stock Exchange opens. The company will also host a webcast discussion at 8:30 a.m. Eastern, with slides and a replay available on its Investor Relations page for 12 months. Historically, such earnings date announcements have led to mild positive stock reactions.
Henry Schein Inc. stock outperforms competitors on strong trading day
Shares of Henry Schein Inc. (HSIC) rose by 3.00% to $74.46 on Monday, outperforming the broader market during a strong trading session. The S&P 500 Index and Dow Jones Industrial Average also saw significant gains. This increase ended a three-day losing streak for the stock.
Why a Full Exit From Cogent Communications Amid a 74% Stock Drop Could Matter for Investors
Ulysses Management has fully exited its position in Cogent Communications (CCOI) by selling 335,982 shares, previously valued at $12.9 million. This move comes as Cogent's stock has dropped 74% over the past year, significantly underperforming the S&P 500. The decision by Ulysses Management, which focuses its portfolio on solid players like Microsoft and Amazon, suggests a preference for companies with better earnings visibility and stronger pricing power over struggling telecom firms.
Tudor Investment Corp ET AL Invests $15.38 Million in Henry Schein, Inc. $HSIC
Tudor Investment Corp ET AL has invested $15.38 million in Henry Schein, Inc. (NASDAQ:HSIC) by acquiring 231,651 shares in Q3, representing a new 0.20% stake in the company. Despite significant institutional ownership, insiders have recently sold shares, including CEO Stanley M. Bergman. Henry Schein recently exceeded Q3 earnings expectations and provided optimistic FY2026 guidance, maintaining a consensus "Hold" rating from analysts.
Align Technology Inc. stock outperforms competitors on strong trading day
Align Technology Inc. stock experienced a strong trading day, outperforming its competitors. The stock closed at $328.66, up 4.25%, while its rivals like Dentsply Sirona Inc. and Henry Schein Inc. saw smaller gains or losses. This performance boosted the company's year-to-date return significantly.
Is It Time To Reassess McKesson (MCK) After Recent Pullback And DCF Valuation Gap
McKesson (MCK) has experienced a recent pullback, declining 5.9% in the past week and 6.5% over the last month, yet it shows strong long-term returns. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 40.2%, with an intrinsic value of $1,481.84 compared to its current price of around $885.84. Additionally, its Price-to-Earnings (P/E) ratio of 25.0x is below Simply Wall St's "Fair Ratio" of 36.2x, also indicating undervaluation based on fundamentals.
Barclays Sticks to Their Buy Rating for Henry Schein (HSIC)
Barclays analyst Glen Santangelo has maintained a Buy rating for Henry Schein (HSIC) with a price target of $86.00, citing the company's recent strong financial performance including increased quarterly revenue and net profit. Despite this positive outlook from Barclays and Piper Sandler, William Blair has issued a Hold rating for HSIC. Additionally, corporate insider sentiment for the stock appears negative, with an increase in insider selling activities recently.
